SAMe Supplement Guide: Benefits, Dosing, Forms, and Safety

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

SAMe (S-adenosyl-L-methionine, also known as SAM-e, ademethionine, or AdoMet) is a naturally occurring compound found in virtually every cell in the body. It is synthesized endogenously from the essential amino acid methionine and adenosine triphosphate (ATP) in a reaction catalyzed by the enzyme methionine adenosyltransferase (MAT) [1][2]. SAMe serves as the principal methyl donor in the body, participating in over 100 methylation reactions that regulate gene expression, neurotransmitter synthesis, protein function, and lipid metabolism [1][2][3]. After donating its methyl group, SAMe is converted to S-adenosylhomocysteine (SAH), which is subsequently hydrolyzed to homocysteine [1][2].

SAMe participates in three critical metabolic pathways [1][2][3]:

• Transmethylation: SAMe donates methyl groups to DNA, RNA, proteins, phospholipids, and small molecules including neurotransmitters. This is the most quantitatively significant pathway. Methylation of phospholipids is essential for cell membrane fluidity and receptor function. Methylation of neurotransmitter precursors contributes to the synthesis of dopamine, serotonin, norepinephrine, and melatonin.
• Transsulfuration: After donating its methyl group, SAMe is converted through a series of steps to homocysteine, which can then be irreversibly converted to cysteine via the transsulfuration pathway. Cysteine is a precursor to glutathione, the body's principal intracellular antioxidant. This pathway requires vitamin B6 as a cofactor.
• Aminopropylation (polyamine synthesis): SAMe serves as the aminopropyl donor for the synthesis of polyamines (spermidine and spermine), which are essential for cell growth, differentiation, and DNA stabilization.

The body's ability to synthesize SAMe depends on adequate supplies of methionine (from dietary protein), folate (as methylfolate, which regenerates methionine from homocysteine), and vitamin B12 (a cofactor for methionine synthase) [1][2]. Deficiencies of folate or B12 impair SAMe production, which may contribute to the neuropsychiatric symptoms seen in B-vitamin deficiency states [2][3].

SAMe levels decline with age and are reduced in several disease states. Cerebrospinal fluid SAMe levels are low in patients with depression, Alzheimer's disease, and HIV-related neurological disease [2][3]. Hepatic SAMe synthesis is impaired in chronic liver disease because the liver is the primary site of SAMe production [4]. These observations have driven interest in SAMe supplementation for depression, osteoarthritis, and liver conditions.

SAMe was first described in 1952 by the Italian biochemist Giulio Cantoni [2]. It has been available as a prescription medication in Italy and other European countries since the 1970s — initially as an injectable formulation and later in oral form. In the United States, SAMe became available as an over-the-counter dietary supplement in 1999 following passage of the Dietary Supplement Health and Education Act [2][3]. It is one of the most extensively studied natural compounds for depression and osteoarthritis, with clinical research spanning more than four decades.

Forms and Bioavailability

Chemical Forms and Stabilization

SAMe in supplements is produced synthetically in several stabilized forms. SAMe is inherently unstable and susceptible to degradation when exposed to moisture, heat, and light [5][6]. To improve stability, SAMe is manufactured as a salt complex with various stabilizing compounds. The stabilizing salt approximately doubles the molecular weight — meaning a tablet containing 200 mg of "S-adenosyl-methionine disulfate tosylate" contains only about 100 mg of actual SAMe. Verify the Supplement Facts panel lists the active SAMe amount, not the total salt weight [5][6].

• Tosylate / disulfate tosylate / disulfate ditosylate — the most common forms in U.S. supplements and the most used in clinical studies. The majority of depression and osteoarthritis research has used these forms [5][6].
• 1,4-butanedisulfonate (Actimet) — used in some European pharmaceutical products. A clinical trial found 1,600 mg of the butanedisulfonate form (providing 800 mg active SAMe) improved depression symptoms comparably to 50 mg imipramine over 6 weeks (Delle Chiaie, Am J Clin Nutr 2002) [7]. One in vitro study found it did not stimulate brain cells compared to free-form SAMe (Travagli, Eur J Pharmacol 1994), though this was in isolated tissue, not in humans [2].

An accurate Supplement Facts label should list the amount of active SAMe separately from the salt complex weight. Most products in the US list the active SAMe amount (e.g., "SAMe 200 mg from 400 mg S-adenosyl-L-methionine disulfate tosylate"), but not all do. There is no definitive evidence that one salt form is clinically superior to another [5][6].

Oral Bioavailability

Oral bioavailability of SAMe is low, estimated at approximately 2–5% due to extensive first-pass metabolism in the gut wall and liver [2][3]. Despite this low bioavailability, oral SAMe supplementation at therapeutic doses (800–1,600 mg/day) has demonstrated clinical efficacy in multiple trials for depression and osteoarthritis, indicating that sufficient SAMe reaches target tissues [2][7][8]. Peak plasma concentrations are reached approximately 3–5 hours after oral ingestion, and the half-life of orally administered SAMe is approximately 100 minutes [2][3].

Enteric Coating and Absorption

Most SAMe supplements use enteric coating to protect the compound from degradation by stomach acid [5][6]. The enteric coating allows the tablet to pass through the stomach intact and dissolve in the more alkaline environment of the small intestine, where SAMe is absorbed. Enteric-coated products also reduce the likelihood of nausea and stomach upset, which are the most common side effects of SAMe supplementation [5][6].

SAMe is generally recommended to be taken on an empty stomach (30–60 minutes before meals) for best absorption, although this recommendation is not strongly supported by pharmacokinetic data [5]. If nausea occurs, taking SAMe with food or switching to an enteric-coated formulation may help [5][6].

Storage Considerations

SAMe attracts moisture from the air (it is hygroscopic), making it susceptible to degradation when exposed to humidity [5][6]. Products in blister packaging — in which each tablet is individually sealed — are preferable to bottles. Products sold in bottles should be kept sealed, stored away from heat and moisture, and any desiccant pack included in the bottle should be retained [5]. A slight yellow color is normal — SAMe is inherently off-white to light yellow [5].

Evidence for Benefits

Depression

SAMe is one of the most extensively studied natural therapies for major depressive disorder (MDD), with research dating back to the 1970s. The evidence suggests SAMe is as effective as older tricyclic antidepressants (TCAs) for treating depression, though it may be less effective than modern selective serotonin reuptake inhibitors (SSRIs) [2][7][8][9][10].

Mechanism: SAMe's antidepressant action is believed to operate through multiple pathways. As the principal methyl donor, SAMe is required for the synthesis and metabolism of monoamine neurotransmitters — serotonin, dopamine, and norepinephrine — that are central to mood regulation [2][3]. SAMe methylates phospholipids in neuronal cell membranes, increasing membrane fluidity and improving neurotransmitter receptor function [2][3]. It also supports the production of glutathione, which protects neurons from oxidative stress, and influences epigenetic gene regulation through DNA and histone methylation — mechanisms increasingly recognized as relevant to depression pathophysiology [2][3].

SAMe vs. tricyclic antidepressants: Several RCTs have demonstrated that SAMe is comparable in efficacy to tricyclic antidepressants for treating major depression:

• Delle Chiaie et al. (Am J Clin Nutr 2002) conducted a double-blind trial comparing 1,600 mg/day of SAMe (as the 1,4-butanedisulfonate form, providing 800 mg active SAMe) to 150 mg/day of imipramine for 6 weeks. SAMe was as effective as imipramine in reducing Hamilton Depression Rating Scale (HAM-D) scores, and was significantly better tolerated — with a substantially lower dropout rate due to adverse effects [7].
• Salmaggi et al. (Psychother Psychosom 1993) compared oral SAMe 1,600 mg/day to imipramine 150 mg/day in a 6-week double-blind trial. Both treatments produced comparable improvements in depression scores, with SAMe showing a more favorable side effect profile [8].
• Kagan et al. (Am J Psychiatry 1990) reported that SAMe at 1,600 mg/day was as effective as imipramine at 150 mg/day in treating major depression, with onset of antidepressant effect within 1–2 weeks [9].

Meta-analysis: Bressa (Acta Neurol Scand Suppl 1994) conducted a meta-analysis of studies comparing SAMe to placebo and to tricyclic antidepressants. The analysis found a global effect size of 17% favoring SAMe over placebo, and confirmed that SAMe was comparable to TCAs in efficacy with a superior side effect profile [10].

SAMe as adjunctive therapy to SSRIs/SRIs: One of the most clinically relevant applications of SAMe is as an add-on treatment for patients who do not respond adequately to standard antidepressant medications. Papakostas et al. (Am J Psychiatry 2010) conducted a randomized, double-blind, placebo-controlled trial in patients with major depressive disorder who had not responded to treatment with a serotonin reuptake inhibitor (SRI). Patients received 800 mg of SAMe twice daily (total 1,600 mg/day) or placebo in addition to their existing SRI for 6 weeks. The response rate was 46.1% in the SAMe group versus 35.8% in the placebo group, and the remission rate was 25.8% versus 11.7% — a statistically significant difference [11].

Lower-dose adjunctive studies (mixed results): Sarris et al. (Eur Neuropsychopharmacol 2018) tested a lower daily dose of SAMe (800 mg total, plus 500 mcg folinic acid and 200 mcg vitamin B12) as an adjunct to antidepressant medication in patients with major depressive disorder. At this lower dose, SAMe did not improve symptoms more than placebo. One suspected serotonergic reaction leading to hospitalization was reported in the SAMe group, though it resolved quickly and serotonin syndrome was not confirmed [12].

Sarris et al. (Psychopharmacology (Berl) 2019) studied the same dose of SAMe (800 mg/day with B vitamins) as monotherapy in 41 people with major depressive disorder who were not taking antidepressants. SAMe produced a slight but statistically significant improvement in symptoms only in those who began the study with the mildest form of depression. There was no significant improvement in those with moderate to severe depression [13].

Dose-response relationship: The evidence suggests a dose-response pattern for SAMe's antidepressant effects. The most consistently positive results come from studies using 1,600 mg/day [7][8][9][11]. The 800 mg/day dose tested by Sarris et al. was not effective as an adjunct to antidepressants [12], suggesting that higher doses may be needed for reliable antidepressant activity.

Osteoarthritis

SAMe has been studied for osteoarthritis of the knee, hip, hand, and spine. The evidence suggests it may reduce pain and disability — though the quality of evidence is mixed and any benefit over placebo may be small [5][14][15][16][17][18].

Mechanism: SAMe is involved in the synthesis of proteoglycans and glycosaminoglycans, which are essential structural components of cartilage [2][3]. In vitro and animal studies have shown that SAMe stimulates chondrocyte proteoglycan synthesis and may have anti-inflammatory properties [2]. SAMe also supports glutathione production, which may reduce oxidative stress in joint tissues [2][3].

SAMe vs. NSAIDs (active comparator trials): The strongest evidence for SAMe in osteoarthritis comes from trials comparing it to nonsteroidal anti-inflammatory drugs, in which SAMe (typically 1,200 mg/day) has performed comparably to conventional anti-inflammatory medications:

• Kim et al. (Clin Ther 2009) compared SAMe 1,200 mg/day to nabumetone (a COX-2 preferential NSAID) in patients with knee osteoarthritis. After 8 weeks, both treatments produced similar improvements in pain and function, although SAMe took longer to reach maximum effect [14].
• Najm et al. (BMC Musculoskelet Disord 2004) compared SAMe 1,200 mg/day to celecoxib 200 mg/day in a crossover trial. At the end of the first month, celecoxib was superior, but by the end of the second month, SAMe and celecoxib were equally effective — supporting the observation that SAMe has a slower onset of action but comparable long-term efficacy [15].
• Muller-Fassbender et al. (Am J Med 1987) compared SAMe 1,200 mg/day to ibuprofen 1,200 mg/day in 150 patients with osteoarthritis over 4 weeks. Both treatments produced equivalent reductions in pain and morning stiffness, but SAMe was significantly better tolerated — with fewer gastrointestinal side effects [16].
• Caruso and Pietrogrande (Am J Med 1987) compared SAMe 1,200 mg/day to placebo in a large multicenter Italian trial of patients with osteoarthritis of the knee, hip, hand, and spine. SAMe was more effective than placebo at reducing pain [17].
• Domljan et al. (Int J Clin Pharmacol Ther Toxicol 1989) found that SAMe 1,200 mg/day for the first week followed by 800 mg/day thereafter was as effective as naproxen (Aleve) for the relief of knee pain [18].

SAMe vs. placebo (mixed results): When compared directly to placebo (rather than active comparator drugs), the results have been less consistently positive. Rutjes et al. (Cochrane Database Syst Rev 2009) performed a Cochrane analysis of SAMe for osteoarthritis and concluded that SAMe did not significantly reduce pain and only slightly improved functional limitation, at best. The authors noted that the quality of available studies was generally low [20]. Soeken et al. (J Fam Pract 2002) similarly found modest effects in a systematic review [21]. SAMe is unlikely to help with severe osteoarthritis with bone-on-bone contact [5].

Onset of action: A consistent finding across trials is that SAMe has a slower onset of action than NSAIDs — typically requiring 2–5 weeks before noticeable pain relief, compared to days for NSAIDs. However, once established, the benefit tends to persist [5][14][15]. The clinical advantage of SAMe over NSAIDs is its superior gastrointestinal tolerability — it does not carry the risk of gastric ulceration, bleeding, or cardiovascular events associated with long-term NSAID use [5][14][15][16].

Depression in Parkinson's Disease

Depression is highly prevalent in Parkinson's disease, affecting 40–50% of patients. SAMe has been investigated as an alternative approach in this population [22][23].

• Carrieri et al. (Curr Ther Res 1990) studied 21 people with Parkinson's disease and comorbid major depression. Patients received 400 mg of oral SAMe twice daily (800 mg/day total) plus 200 mg of SAMe intramuscularly for 30 days. Depression symptoms improved significantly compared to placebo, although motor symptoms of Parkinson's disease were unchanged [22].
• Di Rocco et al. (Mov Disord 2000) conducted an open-label study in 11 people with Parkinson's disease and depression. Patients received 800 to 3,600 mg of SAMe daily for 10 weeks. Depression symptoms improved by at least 50% in all but one patient. While there was no significant change in Parkinson's disease motor symptoms, eight participants reported feeling increased "on" time, and five reported fewer dyskinesias. The study was limited by the absence of a control group [23].

These results are promising but based on very small, methodologically limited studies. There is a potential concern that SAMe might reduce the effectiveness of levodopa over time through its methylation activity (see Drug Interactions section) [24].

Fibromyalgia

Jacobsen et al. (Scand J Rheumatol 1991) conducted a double-blind, placebo-controlled trial in 44 people with fibromyalgia (average age 49). Patients received 400 mg of SAMe twice daily (800 mg/day total) or placebo for six weeks. Compared to placebo, the SAMe group experienced slightly reduced pain at rest and slightly less fatigue. However, there was no significant improvement in tender point score, self-reported pain during physical activity, depression score, use of pain-relieving medications, or quality of sleep compared to placebo [25]. The evidence for SAMe in fibromyalgia is limited to this small trial and suggests marginal benefit at best.

Liver Disease

The liver is the primary site of SAMe synthesis and the organ where the most SAMe is produced and consumed. In chronic liver disease, the activity of methionine adenosyltransferase (MAT) — the enzyme responsible for SAMe synthesis — is impaired, leading to depleted hepatic SAMe levels [2][4]. This has generated interest in SAMe supplementation for various liver conditions.

Mechanism: SAMe is critical for maintaining hepatic glutathione levels, the liver's primary antioxidant defense. It also participates in phospholipid methylation required for bile acid transport and cell membrane integrity [2][4].

Alcoholic liver disease: Mato et al. (J Hepatol 1999) conducted a randomized, double-blind, placebo-controlled trial of 1,200 mg/day SAMe for 2 years in 123 patients with alcoholic liver cirrhosis. In the overall study population, SAMe did not significantly reduce mortality or liver transplantation rates. However, in a pre-specified subgroup analysis excluding the most severely ill patients, SAMe treatment was associated with significantly reduced mortality (12% vs. 29% in the placebo group, p=0.046) [26]. A Cochrane review (Rambaldi and Gluud, Cochrane Database Syst Rev 2006) concluded that there was insufficient high-quality evidence to support or refute SAMe use in alcoholic liver disease [27].

Intrahepatic cholestasis of pregnancy: Several early European trials found that intravenous and oral SAMe (800–1,600 mg/day) improved pruritus and liver function tests in pregnant women with intrahepatic cholestasis. A Cochrane review (Burrows et al., Cochrane Database Syst Rev 2001) found that while SAMe appeared to reduce pruritus, the available studies were small and of variable quality [28].

Metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Noureddin et al. (Exp Biol Med (Maywood) 2015) found that SAMe supplementation in an animal model of MASH helped protect against liver injury, reducing steatosis and inflammation [29]. However, preliminary human research found that SAMe at doses of 1,000–2,000 mg/day for six weeks did not improve liver enzyme levels or markers of fibrosis compared to baseline [5]. The evidence for SAMe in liver disease remains insufficient to make strong clinical recommendations — larger, better-designed trials are needed.

AIDS-Related Myelopathy

SAMe has been investigated for HIV-associated myelopathy, a neurological complication of HIV infection. Cerebrospinal fluid SAMe levels are reduced in HIV-positive patients with neurological symptoms. Preliminary studies have suggested that SAMe supplementation may improve neurological function in this population, though the evidence base is limited to small, uncontrolled studies [2][3].

ADHD in Adults

SAMe has been explored as a treatment for attention deficit-hyperactivity disorder (ADHD) in adults based on its role in neurotransmitter synthesis, particularly dopamine. Arnold et al. (Eur Neuropsychopharmacol 2005) reported that while some patients showed improvement in ADHD symptoms with SAMe supplementation, the study was limited by small sample size and a high rate of side effects at the 1,600 mg/day dose, including drowsiness [30]. The evidence for SAMe in ADHD is preliminary and insufficient to support clinical use for this indication.

Recommended Dosing

Recommended daily doses of SAMe range from 400 to 1,600 mg depending on the condition, its severity, and the individual's response [5][6]. All doses listed below refer to active SAMe content (not the weight of the salt complex). SAMe is typically taken in divided doses (e.g., 400 mg twice daily or 400 mg three times daily) [5][6].

• Depression (monotherapy): 1,600 mg/day (in 2 divided doses); most studies used this dose
• Depression (adjunctive to SSRI/SRI): 1,600 mg/day (800 mg twice daily); note that 800 mg/day was NOT effective as an adjunct [12]
• Osteoarthritis: 1,200 mg/day (in 2–3 divided doses)
• Fibromyalgia: 800 mg/day (in 2 divided doses)
• Liver disease: 1,200–1,600 mg/day (in 2 divided doses)
• Parkinson's disease depression: 800–3,600 mg/day (very small studies only)

Starting dose: It is common practice to start at a lower dose (200–400 mg/day) and increase gradually over 1–2 weeks to the target dose [5][6]. This approach can help minimize gastrointestinal side effects, particularly nausea.

Timing: SAMe is generally taken on an empty stomach to improve absorption [5]. Morning and early afternoon dosing are often recommended, as SAMe can be mildly stimulating in some individuals and may disrupt sleep if taken late in the day [5][6]. However, drowsiness has been reported at higher doses (1,600 mg/day) [30].

Time to benefit: Improvements may take anywhere from a few days to five weeks to become noticeable [5]. For depression, some patients report improvement within 1–2 weeks, though full therapeutic effect typically requires 4–6 weeks [2][9]. For osteoarthritis, most studies show benefit emerging over 2–5 weeks [14][15].

SAMe, Homocysteine, and B Vitamins

SAMe is converted to homocysteine in the body, but short-term studies up to 1,600 mg/day have not shown increased homocysteine levels [20][21]. The body converts homocysteine to glutathione using B6, or recycles it back to methionine using B12 and folate (or TMG as an alternative methyl donor via the BHMT pathway) [22]. As long as dietary B vitamin intake is adequate, additional B supplementation should not be strictly necessary, though ensuring adequate B-vitamin intake is a reasonable precaution, particularly with long-term use [5][31].

Safety and Side Effects

Common Side Effects

SAMe is generally considered safe when taken in appropriate doses [5][6]. The most commonly reported adverse effects are:

• Gastrointestinal: Nausea and stomach upset are the most frequent side effects. These can often be mitigated by taking enteric-coated products, reducing the dose, taking SAMe with food, or taking smaller divided doses [5][6].
• Unusual taste in the mouth: Reported by seven participants in one clinical trial (Sarris, Psychopharmacology (Berl) 2019) [13]. This side effect was not reported by anyone taking placebo.
• Drowsiness: Higher doses of SAMe (1,600 mg/day) have been reported to cause drowsiness in some people (Arnold, Eur Neuropsychopharmacol 2005) [30].
• Anxiety or restlessness: Some individuals report mild stimulation or anxiety, particularly during the initial dose-escalation period [2][6].
• Insomnia: Because SAMe may have mild stimulant properties, it can occasionally interfere with sleep if taken late in the day [5][6].

Serious Concerns

Bipolar disorder: Individuals with bipolar (manic/depressive) disorder should know that SAMe could trigger a manic episode (Cuomo, Ann Gen Psychiatry 2020) [34]. This is a risk shared with conventional antidepressants and is particularly concerning because SAMe is available over-the-counter. People with known or suspected bipolar disorder should not take SAMe without physician guidance.

Serotonergic reaction: A suspected serotonergic reaction (symptoms including agitation, sweating, high body temperature, and diarrhea) leading to hospitalization was reported in one individual taking 800 mg of SAMe daily in addition to antidepressant medication. The reaction resolved quickly and was not confirmed as serotonin syndrome (Sarris, Eur Neuropsychopharmacol 2018) [12]. This case underscores the importance of medical supervision when combining SAMe with serotonergic medications.

Potential formation of toxic metabolites: Laboratory studies in mice and cell cultures suggest that excess SAMe supplementation can lead to the formation of adenine and methylthioadenosine, compounds that are potentially toxic at high concentrations. Excess SAMe can essentially reverse its normal role, disrupting rather than supporting methylation reactions. However, feeding mice SAMe in amounts proportionate to typical human supplementation doses did not adversely affect body weight or physical condition over one month, though it did lengthen normal circadian rhythms (Fukumoto, Commun Biol 2022) [35].

Homocysteine Concerns

Because SAMe is converted to homocysteine after donating its methyl group, there has been theoretical concern that SAMe supplementation could raise homocysteine levels. However, short-term studies with daily SAMe doses of up to 1,600 mg have not demonstrated increases in homocysteine levels (Thompson, J Altern Complement Med 2009; Goren, Pharmacotherapy 2004) [32][33]. The body normally eliminates homocysteine by converting it to glutathione (via the transsulfuration pathway, requiring B6) or recycling it back to methionine (requiring folate, B12, or TMG) [5][31]. As long as B-vitamin intake is adequate, homocysteine accumulation from SAMe supplementation appears unlikely with short-term use. Long-term data are more limited.

Who Should Avoid SAMe

• Individuals with bipolar disorder (risk of manic episode) [34]
• People taking MAO inhibitors (risk of serotonergic crisis) [5][6]
• Those taking SSRIs, SNRIs, or tricyclic antidepressants without physician supervision [5][12]
• Pregnant or breastfeeding women (insufficient safety data for supplementation at therapeutic doses) [5][6]
• Individuals with Parkinson's disease taking levodopa (potential interaction — see Drug Interactions) [24]

Drug Interactions

SAMe's role as a methyl donor and its involvement in neurotransmitter synthesis create the potential for clinically significant drug interactions, particularly with medications that affect serotonin, dopamine, and methylation pathways.

• Antidepressants (SSRIs, SNRIs, MAO inhibitors, tricyclics): SAMe should not be taken with antidepressants without physician supervision due to risk of serotonergic reactions [7][12]. SSRIs and SNRIs may have additive serotonergic effects; MAO inhibitors pose the risk of hypertensive crisis and serotonin syndrome and should not be combined with SAMe [5][6].
• Triptans and tramadol: These medications have serotonergic properties; use caution and consult a physician before combining with SAMe [5].
• Levodopa (Parkinson's disease): SAMe may help relieve the depression that commonly accompanies Parkinson's disease, but there is concern that SAMe could reduce the effectiveness of levodopa over time (Muller, Clin Neuropharmacol 2005) [24]. The theoretical mechanism involves SAMe methylating levodopa via catechol-O-methyltransferase (COMT), accelerating its breakdown. People on levodopa should use SAMe only under close neurological supervision.
• Bipolar disorder: SAMe can trigger manic episodes in people with bipolar disorder [34].
• Dextromethorphan (DXM): Found in many over-the-counter cough medications. DXM has serotonergic properties, and combining it with SAMe could theoretically increase serotonergic risk [5].
• Diabetes medications: SAMe has been reported to lower blood sugar in some individuals. Those taking insulin or oral diabetes medications should monitor blood sugar more closely if starting SAMe [6].

Dietary Sources

SAMe is not obtained directly from food — it is synthesized in the body from the amino acid methionine in a reaction that also requires ATP [1][2]. However, the body's ability to produce SAMe depends on adequate dietary intake of three key nutrients:

Methionine

Methionine is an essential amino acid that serves as the direct precursor for SAMe synthesis. It is found in protein-rich foods including meat, fish, dairy, eggs, nuts, and seeds. The recommended daily intake of methionine (combined with cysteine) is approximately 19 mg/kg body weight in adults, or about 1,330 mg/day for a 70 kg person [36]. Most omnivorous diets easily meet this requirement. Vegans and vegetarians may have lower methionine intake but can meet requirements through legumes, grains, nuts, and seeds.

Folate (as Methylfolate)

Folate is required to regenerate methionine from homocysteine, maintaining the methionine-SAMe cycle. Methyltetrahydrofolate (MTHF, methylfolate) is the active form that serves as the methyl donor in this reaction. Good dietary sources include leafy green vegetables (spinach, kale), legumes, asparagus, Brussels sprouts, avocado, and fortified cereals [1][2][31]. The RDA for folate is 400 mcg DFE (dietary folate equivalents) for adults. Approximately 40% of the population carries MTHFR gene variants that reduce the conversion of dietary folate to its active methylfolate form, potentially impairing SAMe production [31]. Supplemental methylfolate (5-MTHF) bypasses this genetic bottleneck.

Vitamin B12

Vitamin B12 is a cofactor for methionine synthase, the enzyme that converts homocysteine back to methionine using a methyl group from methylfolate. B12 deficiency impairs this recycling process, reducing SAMe production and leading to elevated homocysteine. Dietary sources include meat, fish, dairy, eggs, and fortified foods. The RDA is 2.4 mcg for adults [1][2][31].

Vitamin B6

Vitamin B6 (pyridoxine) is required for the transsulfuration pathway — the alternative route for homocysteine disposal that converts homocysteine to cysteine (and ultimately to glutathione) rather than recycling it to methionine. Adequate B6 ensures that homocysteine generated from SAMe metabolism can be efficiently cleared. Dietary sources include poultry, fish, potatoes, bananas, and fortified cereals [1][2].

No food contains pre-formed SAMe in meaningful amounts. Supporting endogenous SAMe production requires adequate protein intake (for methionine), adequate folate, B12, and B6 intake (for homocysteine recycling and disposal), and adequate ATP production (general metabolic health). Individuals with low protein intake, B-vitamin deficiencies, or chronic liver disease (which impairs the MAT enzyme) may have suboptimal SAMe production and may be more likely to benefit from SAMe supplementation [2][4].

References

1. Bottiglieri T. "S-Adenosyl-L-methionine (SAMe): from the bench to the bedside — molecular basis of a pleiotrophic molecule." Am J Clin Nutr. 2002;76(5):1151S-1157S. https://doi.org/10.1093/ajcn/76.5.1151S
2. Galizia I, Oldani L, Macritchie K, et al. "S-adenosyl methionine (SAMe) for depression in adults." Cochrane Database Syst Rev. 2016;10(10):CD011286. https://doi.org/10.1002/14651858.CD011286.pub2
3. Mischoulon D, Fava M. "Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence." Am J Clin Nutr. 2002;76(5):1158S-1161S. https://doi.org/10.1093/ajcn/76.5.1158S
4. Mato JM, Lu SC. "Role of S-adenosyl-L-methionine in liver health and injury." Hepatology. 2007;45(5):1306-1312. https://doi.org/10.1002/hep.21650
5. ConsumerLab. "SAMe Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/sam-e-review-comparisons/same/
6. National Institutes of Health, National Center for Complementary and Integrative Health. "S-Adenosyl-L-Methionine (SAMe): In Depth." https://www.nccih.nih.gov/health/s-adenosyl-l-methionine-same-in-depth
7. Delle Chiaie R, Pancheri P, Scapicchio P. "Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies." Am J Clin Nutr. 2002;76(5):1172S-1176S. https://doi.org/10.1093/ajcn/76.5.1172S
8. Salmaggi P, Bressa GM, Nicchia G, et al. "Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women." Psychother Psychosom. 1993;59(1):34-40. https://doi.org/10.1159/000288642
9. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. "Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial." Am J Psychiatry. 1990;147(5):591-595. https://doi.org/10.1176/ajp.147.5.591
10. Bressa GM. "S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies." Acta Neurol Scand Suppl. 1994;154:7-14. https://doi.org/10.1111/j.1600-0404.1994.tb05403.x
11. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. "S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial." Am J Psychiatry. 2010;167(8):942-948. https://doi.org/10.1176/appi.ajp.2009.09081198
12. Sarris J, et al. "S-adenosyl methionine (SAMe) as adjunctive treatment for depression — results of a randomized, double-blind, placebo-controlled trial." Eur Neuropsychopharmacol. 2018.
13. Sarris J, et al. "S-adenosyl methionine (SAMe) monotherapy for depression: results of a randomized, double-blind, placebo-controlled trial." Psychopharmacology (Berl). 2019.
14. Kim J, Lee EY, Koh EM, et al. "Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis." Clin Ther. 2009;31(12):2860-2872. https://doi.org/10.1016/j.clinthera.2009.12.016
15. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. "S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial." BMC Musculoskelet Disord. 2004;5:6. https://doi.org/10.1186/1471-2474-5-6
16. Muller-Fassbender H. "Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis." Am J Med. 1987;83(5A):81-83. https://doi.org/10.1016/0002-9343(87)90857-8
17. Caruso I, Pietrogrande V. "Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease." Am J Med. 1987;83(5A):66-71. https://doi.org/10.1016/0002-9343(87)90854-2
18. Domljan Z, et al. "A double-blind trial of ademetionine vs naproxen in activated gonarthrosis." Int J Clin Pharmacol Ther Toxicol. 1989;27(7):329-333.
19. Bradley JD, Flusser D, Katz BP, et al. "A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis." J Rheumatol. 1994;21(5):905-911. PMID: 8064732
20. Rutjes AWS, Nüesch E, Reichenbach S, Jüni P. "S-Adenosylmethionine for osteoarthritis of the knee or hip." Cochrane Database Syst Rev. 2009;(4):CD007321. https://doi.org/10.1002/14651858.CD007321.pub2
21. Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. "Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis." J Fam Pract. 2002;51(5):425-430. PMID: 12019049
22. Carrieri PB, Indaco A, Gentile S, et al. "S-adenosylmethionine treatment of depression in patients with Parkinson's disease: a double-blind, crossover study versus placebo." Curr Ther Res. 1990;48(1):154-160.
23. Di Rocco A, Rogers JD, Brown R, Werner P, Bhatt K. "S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial." Mov Disord. 2000;15(6):1225-1229. https://doi.org/10.1002/1531-8257(200011)15:6<1225::AID-MDS1025>3.0.CO;2-A
24. Muller T, et al. "Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease." Clin Neuropharmacol. 2005.
25. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. "Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation." Scand J Rheumatol. 1991;20(4):294-302. https://doi.org/10.3109/03009749109096803
26. Mato JM, Cámara J, Fernández de Paz J, et al. "S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial." J Hepatol. 1999;30(6):1081-1089. https://doi.org/10.1016/S0168-8278(99)80263-3
27. Rambaldi A, Gluud C. "S-adenosyl-L-methionine for alcoholic liver diseases." Cochrane Database Syst Rev. 2006;(2):CD002235. https://doi.org/10.1002/14651858.CD002235.pub2
28. Burrows RF, Clavisi O, Burrows E. "Interventions for treating cholestasis in pregnancy." Cochrane Database Syst Rev. 2001;(4):CD000493. https://doi.org/10.1002/14651858.CD000493
29. Noureddin M, Mato JM, Lu SC. "Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine." Exp Biol Med (Maywood). 2015;240(6):809-820. https://doi.org/10.1177/1535370215579161
30. Arnold LE, et al. "S-adenosyl-L-methionine (SAMe) in adults with ADHD." Eur Neuropsychopharmacol. 2005.
31. Obeid R, et al. "Mechanisms of homocysteine metabolism and B-vitamin interactions." Nutrients. 2013.
32. Thompson MA, et al. "Effects of S-adenosyl-L-methionine on homocysteine levels." J Altern Complement Med. 2009.
33. Goren JL, et al. "Bioavailability and lack of effect on homocysteine levels of oral SAMe in a double-blind, crossover study in healthy volunteers." Pharmacotherapy. 2004.
34. Cuomo A, et al. "S-adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review." Ann Gen Psychiatry. 2020;19:50. https://doi.org/10.1186/s12991-020-00298-z
35. Fukumoto K, et al. "Excess S-adenosylmethionine inhibits methylation via catabolism to adenine." Commun Biol. 2022;5:313. https://doi.org/10.1038/s42003-022-03280-5
36. U.S. Department of Agriculture, FoodData Central. https://fdc.nal.usda.gov/